Rucha Vadia, PhD (Dr. rer. oec.), is a Health Economics and Payer Evidence Manager at AstraZeneca, based in Brussels, Belgium. She supports reimbursement negotiations through HEPE submissions and leads payer evidence activities across the pharmaceutical portfolio. Since 2024, Rucha has also held a global assignment with AstraZeneca’s Commercial Digital Health team, focusing on AI-driven payer value demonstration strategies for key international markets.

AstraZeneca is a global, science-led, patient-focused pharmaceutical company. We are dedicated to transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. We are a global, science-led, patient-focused pharmaceutical company seeking to unlock the power of what science can do. Our strategy is consistent but dynamic. Our business is organised to deliver our growth through innovation strategy and achieve our purpose of pushing the boundaries of science to deliver life-changing medicines. Our R&D and Commercial functions promote accelerated decision making and the launches of new medicines across our therapy areas: Oncology, BioPharmaceuticals, and Rare Disease. Inspired by our Values and what science can do, we are focused on accelerating the delivery of life-changing medicines that create enduring value for patients, society and our shareholders. We are committed to operating sustainably, in a way that recognises the interconnection between business growth, the needs of society and the limitations of our planet.